Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 4.75
CBRX's Cash to Debt is ranked higher than
81% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. CBRX: 4.75 )
CBRX' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 4.75

Equity to Asset 0.78
CBRX's Equity to Asset is ranked higher than
85% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. CBRX: 0.78 )
CBRX' s 10-Year Equity to Asset Range
Min: -1.03   Max: 0.85
Current: 0.78

-1.03
0.85
F-Score: 5
Z-Score: -1.61
M-Score: -3.06
WACC vs ROIC
4.24%
29.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 11.75
CBRX's Operating margin (%) is ranked higher than
80% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. CBRX: 11.75 )
CBRX' s 10-Year Operating margin (%) Range
Min: -717.08   Max: 53.25
Current: 11.75

-717.08
53.25
Net-margin (%) 10.44
CBRX's Net-margin (%) is ranked higher than
81% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. CBRX: 10.44 )
CBRX' s 10-Year Net-margin (%) Range
Min: -735.65   Max: 47.67
Current: 10.44

-735.65
47.67
ROE (%) 8.08
CBRX's ROE (%) is ranked higher than
78% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. CBRX: 8.08 )
CBRX' s 10-Year ROE (%) Range
Min: -43413.7   Max: 35088.89
Current: 8.08

-43413.7
35088.89
ROA (%) 6.26
CBRX's ROA (%) is ranked higher than
82% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. CBRX: 6.26 )
CBRX' s 10-Year ROA (%) Range
Min: -158.02   Max: 62.26
Current: 6.26

-158.02
62.26
ROC (Joel Greenblatt) (%) 20.62
CBRX's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. CBRX: 20.62 )
CBRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2550   Max: 1051.31
Current: 20.62

-2550
1051.31
Revenue Growth (3Y)(%) -7.40
CBRX's Revenue Growth (3Y)(%) is ranked higher than
55% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. CBRX: -7.40 )
CBRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -41.8   Max: 85.1
Current: -7.4

-41.8
85.1
EBITDA Growth (3Y)(%) -33.30
CBRX's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. CBRX: -33.30 )
CBRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -73.3   Max: 254
Current: -33.3

-73.3
254
EPS Growth (3Y)(%) -44.10
CBRX's EPS Growth (3Y)(%) is ranked higher than
54% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. CBRX: -44.10 )
CBRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.7   Max: 132.2
Current: -44.1

-45.7
132.2
» CBRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CBRX Guru Trades in Q1 2014

Jim Simons 124,050 sh (-24.47%)
» More
Q2 2014

CBRX Guru Trades in Q2 2014

Jim Simons 94,750 sh (-23.62%)
» More
Q3 2014

CBRX Guru Trades in Q3 2014

Jim Simons 98,950 sh (+4.43%)
» More
Q4 2014

CBRX Guru Trades in Q4 2014

Jim Simons 111,006 sh (+12.18%)
» More
» Details

Insider Trades

Latest Guru Trades with CBRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.30
CBRX's P/E(ttm) is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. CBRX: 22.30 )
CBRX' s 10-Year P/E(ttm) Range
Min: 4.79   Max: 296.3
Current: 22.3

4.79
296.3
Forward P/E 5.76
CBRX's Forward P/E is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. CBRX: 5.76 )
N/A
PE(NRI) 19.30
CBRX's PE(NRI) is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. CBRX: 19.30 )
CBRX' s 10-Year PE(NRI) Range
Min: 2.15   Max: 27.56
Current: 19.3

2.15
27.56
P/B 1.58
CBRX's P/B is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. CBRX: 1.58 )
CBRX' s 10-Year P/B Range
Min: 1.35   Max: 63.23
Current: 1.58

1.35
63.23
P/S 1.98
CBRX's P/S is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. CBRX: 1.98 )
CBRX' s 10-Year P/S Range
Min: 1.45   Max: 15.81
Current: 1.98

1.45
15.81
PFCF 13.02
CBRX's PFCF is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. CBRX: 13.02 )
CBRX' s 10-Year PFCF Range
Min: 9.81   Max: 257.95
Current: 13.02

9.81
257.95
POCF 9.22
CBRX's POCF is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. CBRX: 9.22 )
CBRX' s 10-Year POCF Range
Min: 6.56   Max: 133.33
Current: 9.22

6.56
133.33
EV-to-EBIT 13.42
CBRX's EV-to-EBIT is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. CBRX: 13.42 )
CBRX' s 10-Year EV-to-EBIT Range
Min: -35.8   Max: 202.5
Current: 13.42

-35.8
202.5
Current Ratio 4.44
CBRX's Current Ratio is ranked higher than
84% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. CBRX: 4.44 )
CBRX' s 10-Year Current Ratio Range
Min: 0.68   Max: 9.58
Current: 4.44

0.68
9.58
Quick Ratio 3.90
CBRX's Quick Ratio is ranked higher than
85% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. CBRX: 3.90 )
CBRX' s 10-Year Quick Ratio Range
Min: 0.39   Max: 8.88
Current: 3.9

0.39
8.88
Days Inventory 60.24
CBRX's Days Inventory is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. CBRX: 60.24 )
CBRX' s 10-Year Days Inventory Range
Min: 59.68   Max: 182.5
Current: 60.24

59.68
182.5
Days Sales Outstanding 59.47
CBRX's Days Sales Outstanding is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. CBRX: 59.47 )
CBRX' s 10-Year Days Sales Outstanding Range
Min: 16.38   Max: 137.6
Current: 59.47

16.38
137.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.98
CBRX's Price/Net Cash is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CBRX: 11.98 )
CBRX' s 10-Year Price/Net Cash Range
Min: 2.41   Max: 22.47
Current: 11.98

2.41
22.47
Price/Net Current Asset Value 4.28
CBRX's Price/Net Current Asset Value is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CBRX: 4.28 )
CBRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.83   Max: 682.35
Current: 4.28

1.83
682.35
Price/Tangible Book 2.30
CBRX's Price/Tangible Book is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CBRX: 2.30 )
CBRX' s 10-Year Price/Tangible Book Range
Min: 1.58   Max: 264.86
Current: 2.3

1.58
264.86
Price/DCF (Projected) 3.49
CBRX's Price/DCF (Projected) is ranked higher than
81% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. CBRX: 3.49 )
CBRX' s 10-Year Price/DCF (Projected) Range
Min: 3.26   Max: 14.69
Current: 3.49

3.26
14.69
Price/Median PS Value 0.58
CBRX's Price/Median PS Value is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. CBRX: 0.58 )
CBRX' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 20.68
Current: 0.58

0.53
20.68
Price/Graham Number 1.39
CBRX's Price/Graham Number is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. CBRX: 1.39 )
CBRX' s 10-Year Price/Graham Number Range
Min: 0.66   Max: 42.55
Current: 1.39

0.66
42.55
Earnings Yield (Greenblatt) 7.50
CBRX's Earnings Yield (Greenblatt) is ranked higher than
91% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. CBRX: 7.50 )
CBRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 54.1
Current: 7.5

0.5
54.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CLB1.Germany,
Columbia Laboratories, Inc., is engaged in the business of developing, manufacturing and selling pharmaceutical products that utilize its proprietary bioadhesive drug delivery technologies to treat various medical conditions. It is focused in developing drugs that improve treatment options for women's health, an area where it have a rich heritage and proven capabilities. It has developed and brought to market five bioadhesive vaginal gel products that provide patient-friendly solutions for infertility, pregnancy support, amenorrhea, and other gynecologic conditions. The Company's Progesterone Products include Crinone and Prochieve. Crinone is a sustained release gel that delivers natural progesterone vaginally. Crinone utilizes the company's patented BDS, which enables the progesterone to achieve a preferential uptake of drug from the vagina to the uterus, or a "First Uterine Pass Effect." The product is available in both 4% and 8% concentrations, and in the U.S. is also known under the trade name Prochieve. Women's Health Market include STRIANT which utilizes the BDS to achieve controlled and sustained delivery of testosterone via the buccal cavity - the small depression in the mouth where the gum meets the upper lip above the incisor teeth. STRIANT is absorbed into the bloodstream and delivers testosterone directly into the superior vena cava (major blood vessel), bypassing the gastrointestinal system and liver. All of the products it has developed utilize its Bioadhesive Delivery System ("BDS"), which consists mainly of a polymer (polycarbophil) and an active ingredient. The BDS is based upon the principle of bioadhesion, a process by which the polymer adheres to epithelial surfaces or mucosa. Its vaginal products adhere to the vaginal epithelium; the buccal products adhere to the mucosal membrane of the gum and cheek. The polymer remains attached to epithelial surfaces or mucosa and is discharged upon normal cell turnover, a physiological process that, depending upon the area of the body, occurs every 12 to 72 hours, or longer. Both vaginal and buccal BDS products provide sustained and controlled delivery of active drug ingredients. Its extended period of attachment permits use of BDS in products when extended duration of effectiveness is desirable or required. It's Crinone and Prochieve vaginal gel products are manufactured in bulk by Fleet Laboratories Limited, Watford, Herts, United Kingdom ("Fleet") and filled into overwrapped single-use disposable applicators by Maropack AG, Zell, Switzerland ("Maropack"). Its customers include trade customers, such as drug wholesalers, specialty pharmacies, and chain drug stores, and its marketing partners. The Company and its marketing partners compete against established pharmaceutical and consumer product companies which market products addressing similar needs.
» More Articles for CBRX

Headlines

Articles On GuruFocus.com
Top Gainers of More Than 30% Within One Day Jan 19 2012 
Columbia Laboratories Inc. Reports Operating Results (10-K) Mar 10 2011 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Dec 29 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Dec 28 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Dec 28 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q) Nov 04 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q) Aug 05 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q/A) Jul 30 2010 
Columbia Laboratories Inc. Reports Operating Results (10-Q) May 06 2010 
Columbia Laboratories Inc. Reports Operating Results (10-K/A) Apr 30 2010 

More From Other Websites
COLUMBIA LABORATORIES INC Financials Mar 24 2015
COLUMBIA LABORATORIES INC Files SEC form 8-K, Financial Statements and Exhibits Mar 18 2015
Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results Mar 18 2015
COLUMBIA LABORATORIES INC Files SEC form 10-K, Annual Report Mar 18 2015
Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results Mar 18 2015
Federal Appeals Court Affirms Dismissal of Class Action Lawsuit Mar 12 2015
Federal Appeals Court Affirms Dismissal of Class Action Lawsuit Mar 12 2015
Columbia Laboratories to Discuss Fourth Quarter and Full Year 2014 Financial Results on March 18th... Mar 10 2015
Columbia Laboratories to Discuss Fourth Quarter and Full Year 2014 Financial Results on March 18th... Mar 10 2015
Columbia Laboratories to Present at the 27th Annual ROTH Conference Mar 03 2015
Columbia Laboratories to Present at the 27th Annual ROTH Conference Mar 03 2015
Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10%... Feb 26 2015
Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10%... Feb 26 2015
Highline Research Advisors Initiates on Columbia Laboratories, Inc. with a Buy Rating Feb 25 2015
Highline Research Advisors Initiates on Columbia Laboratories, Inc. with a Buy Rating Feb 25 2015
Columbia Laboratories Announces Date of 2015 Annual Meeting of Stockholders Feb 05 2015
Columbia Laboratories to Present at the 17th Annual BIO CEO & Investor Conference Feb 02 2015
COLUMBIA LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jan 30 2015
Columbia Laboratories Announces Search For New Board Member, Impending Retirement of Chairman... Jan 29 2015
COLUMBIA LABORATORIES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK